Brand and Other Names:Cubicin
- Classes: Lipopeptides
Dosing & Uses
Dosage Forms & Strengths
lyophilized powder for reconstitution
Staphylococcus Aureus Bacteremia (Including Endocarditis)
Complicated Skin & Skin Structure Gram-Positive Bacterial Infections
6 mg/kg IV q24hr for 2-4 weeks
Spectrum of action
- Staphylococcus aureus (including MRSA)
- Streptococcus pyogenes
- Streptococcus agalactiae
- Streptococcus dysgalactiae ssp equisimilis
- Enterococcus faecalis (vancomycin-susceptible)
- CrCl <30 mL/min: Give same dose q48hr
- On hemodialysis days, administer after hemodialysis
Monitor creatine phosphokinase (CPK)
<18 years: Safety and efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Pharyngolaryngeal pain (8.0%)
Chest pain (7.0%)
Elevated blood creatine phosphokinase (7.0%)
Abdominal pain (6.0%)
Abnormal LFTs (3.0%)
Immune system disorders: Anaphylaxis; hypersensitivity reactions, including angioedema, drug rash with eosinophilia and systemic symptoms (DRESS), pruritus, hives, shortness of breath, difficulty swallowing, truncal erythema, and pulmonary eosinophilia; consider treatment with systemic steroids
Infections and infestations: Clostridium difficile–associated diarrhea
Musculoskeletal disorders: myoglobin increased; rhabdomyolysis;
Respiratory, thoracic, and mediastinal disorders: Cough, eosinophilic pneumonia
Nervous system disorders: Peripheral neuropathy
Skin and subcutaneous tissue disorders: Serious skin reactions, including Stevens-Johnson syndrome and vesiculobullous rash
Gastrointestinal disorders: Nausea, vomiting
Special senses: Visual disturbances
Pseudomembranous colitis has been reported; may range from mild to life-threatening
Use cautiously in patients with peripheral neuropathies and myopathy; consider discontinuation
Discontinue with symptoms of myopathy and CPK >1000 U/L (>5x ULN), or no symptoms and CPK >2000 U/L (>10x ULN)
CPK elevations more prevalent if dosed more frequently than q24hr
Consider suspending statins during daptomycin therapy; theoretical risk of additive myopathy
Monitor INR closely for several days if on warfarin
May cause eosinophilic pneumonia characterized by fever, cough, shortness of breath, and difficulty breathing; may result in progressive respiratory failure and is potentially fatal
Prolonged use may result in fungal or bacterial superinfection
Perform susceptibility testing and rule out sequestered foci of infection if persisting or relapsing S. aureus bacteremia/endocarditis occurs
Evaluate patients for Clostridium difficile if diarrhea occurs
Avoid use in pediatric patients <12 months; potential nervous system or muscular system effects
Decreased efficacy reported in patients with moderate baseline renal impairment
Pregnancy & Lactation
Pregnancy category: B
Lactation: Present in human milk but is poorly bioavailable orally; use caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Cyclic lipopeptide: Binds to bacterial membranes and causes rapid depolarization of membrane potential; causes inhibition of protein, DNA, RNA synthesis, and bacterial cell death
Peak plasma time
- 0.5-0.8 hr
Peak plasma concentration
- 4 mg/kg dose: 58 mcg/mL
- 6 mg/kg dose: 94 mcg/mL
- 4 mg/kg dose: 494 mcg•hr/mL
- 6 mg/kg dose: 632 mcg•hr/mL
Protein bound: 92%
Vd: 0.1 L/kg
Half-life: 8 hr
Dialyzable: 11-15% of dose removed by continuous ambulatory peritoneal dialysis/hemodialysis
Renal clearance: 3.7-4.8 mL/hr/kg
Total body clearance: 8-9 mL/hr/kg
Excretion: Urine (78%)
Solution: Dextrose-containing diluents
Do not admix with other drugs
Solution: NS, LR
Reconstitute 500 mg vial with 10 mL NS; dilute further with NS for infusion using aseptic technique (no preservatives or bacteriostatic agents)
Reconstituted solution and diluted infusion solution stable for 12 hr at room temperature and 48 hr at 2-8°C, but do not exceed combined storage time of 12 hr at room temperature and 48 hr refrigerated
Administer intravenously in 0.9% sodium chloride either by injection over 2 min or infusion over 30 min
Do not use in conjunction with ReadyMED elastometric infusion pumps
On hemodialysis days, administer after hemodialysis
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs